| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01c1e0bc0628f76dea731cda5a666ca1 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate |
1987-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74f73f13d4db5d8a5dc86da0932000a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd0b6e397a7bd1097eeb5041cb29976d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a36a8e7d01ec52250f6bbc8d2a68262a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf5d92f2f2a80ceae33ffbfb99bc20b1 |
| publicationDate |
1989-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-S6485085-A |
| titleOfInvention |
Anti-human lymphotoxin monoclonal antibody, its immobilized product, its labeled compound, hybridoma producing said antibody and their production |
| abstract |
PURPOSE:To produce an anti-human lymphotoxin monoclonal antibody, by synthesizing a hybridoma using an antigen consisting of a peptide containing the amino acid sequence of human lymphotoxin and free from cytotoxicity. CONSTITUTION:A peptide containing the total or a part of the amino acid sequence of human lymphotoxin and free from cytotoxicity is used as an antigen to synthesize a hybridoma capable of producing an anti-human lymphotoxin monoclonal antibody (anti-LTMoAb). The hybridoma is cultured and the objective anti-LTMoAb is recovered from the supernatant liquid of the cultured product by a proper method. As an alternative method, the hybridoma is transplanted into the abdominal cavity of a mouse preliminarily subjected to pristane-treatment to effect the proliferation of the hybridoma and the anti- LTMoAb is recovered from the ascites of the mouse. |
| priorityDate |
1987-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |